Journal
CURRENT OPINION IN STRUCTURAL BIOLOGY
Volume 71, Issue -, Pages 180-192Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.sbi.2021.06.015
Keywords
RAS; GTPase; Post-translational modification; Signaling; Cancer
Categories
Funding
- [R35GM134962]
- [5P01CA20365]
- [R35CA 253178]
- [R01CA163489]
- [RO1CA211687]
- [R03TR00 3358]
Ask authors/readers for more resources
Mutations in RAS genes are the most common driving force behind cancer development. RAS proteins, acting as binary molecular switches, control cellular growth through a complex signaling pathway. In addition to nucleotide-binding properties, RAS proteins are also regulated by numerous post-translational modifications, which are currently a high priority for drug discovery research in the field of RAS biology.
Mutations of RAS genes drive cancer more frequently than any other oncogene. RAS proteins integrate signals from a wide array of receptors and initiate downstream signaling through pathways that control cellular growth. RAS proteins are fundamentally binary molecular switches in which the off/on state is determined by the binding of GDP or GTP, respectively. As such, the intrinsic and regulated nucleotide-binding and hydrolytic properties of the RAS GTPase were historically believed to account for the entirety of the regulation of RAS signaling. However, it is increasingly clear that RAS proteins are also regulated by a vast array of post-translational modifications (PTMs). The current challenge is to understand what are the functional consequences of these modifications and which are physiologically relevant. Because PTMs are catalyzed by enzymes that may offer targets for drug discovery, the study of RAS PTMs has been a high priority for RAS biologists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available